In vivo experiments similarly indicated that SLC50A1 expression affects tumor growth rates and DOX resistance, suggesting that SLC50A1 might facilitate DNA damage repair in DOX-treated HCC cells via the glycolytic pathway. Here, SLC50A1 is linked to neoplasm.